Roche News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

10.02.23	[Ad hoc-Mitteilung gemäss Art. 53 KR] Transaktion in Roche Inhaberaktien (GlobeNewswire)
10.02.23	New phase III data show Roche’s Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO) (GlobeNewswire)
14.11.22	[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease (GlobeNewswire)
09.11.22	STRONG-HF study results demonstrate clear benefits for acute heart failure patients (GlobeNewswire)
03.11.22	Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs (GlobeNewswire)
27.10.22	Positive topline phase III results show Roche's Vabysmo improved vision for people living with retinal vein occlusion (RVO) (GlobeNewswire)
26.10.22	Early treatment with Roche's OCREVUS leads to reduced disease progression and healthcare costs; nine-year safety data reinforce favourable benefit-risk profile (GlobeNewswire)
24.10.22	Roche receives FDA clearance for COVID-19 PCR test for use on cobas 6800/8800 Systems (GlobeNewswire)
19.10.22	Roche to present new OCREVUS (ocrelizumab) data in multiple sclerosis and continued research into neuromyelitis optica spectrum disorder at ECTRIMS 2022 (GlobeNewswire)
18.10.22	[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022 (GlobeNewswire)
18.10.22	[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit soliden Ergebnissen in den ersten neun Monaten 2022 (GlobeNewswire)
12.10.22	Roche to introduce its next-generation portfolio of SARS-CoV-2 rapid antigen tests (“2.0”) under CE Mark for self-test and professional use (GlobeNewswire)
12.10.22	Positive new data for Roche’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA) (GlobeNewswire)
11.10.22	Roche launches PRAME (EPR20330) Antibody to identify PRAME protein expression in patients that may have melanoma (GlobeNewswire)
05.10.22	Roche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022 (GlobeNewswire)
04.10.22	Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for ENHERTU (GlobeNewswire)
03.10.22	[Ad hoc announcement pursuant to Art. 53 LR] Roche: Change in the Corporate Executive Committee in January 2023 (GlobeNewswire)
03.10.22	[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche: Wechsel in der Konzernleitung im Januar 2023 (GlobeNewswire)
26.09.22	Change in the Roche Board of Directors (GlobeNewswire)
19.09.22	European Commission approves Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss (GlobeNewswire)
23.08.22	Roche launches a digital PCR system, a powerful new diagnostics platform in the fight against cancer and other diseases (GlobeNewswire)
16.08.22	FDA accepts supplemental Biologics License Application for Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma (GlobeNewswire)
15.08.22	Roche launches new diagnostic test for the better understanding of immune response to SARS-CoV-2 (GlobeNewswire)
12.08.22	Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older (GlobeNewswire)
02.08.22	Roche’s subcutaneous formulation of Tecentriq demonstrates positive Phase III results (GlobeNewswire)
28.07.22	Roche to present scientific progress across Alzheimer’s disease pharmaceutical and diagnostic portfolio at 2022 AAIC Annual Meeting (GlobeNewswire)
22.07.22	CHMP recommends EU approval of Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss (GlobeNewswire)
21.07.22	[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche: Wechsel im VR-Präsidium und in der Konzernleitung im Frühling 2023 (GlobeNewswire)
21.07.22	[Ad hoc announcement pursuant to Art. 53 LR] Roche: Change in the Board of Directors and Corporate Executive Committee in Spring 2023 (GlobeNewswire)
21.07.22	[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche mit guten Halbjahresergebnissen (GlobeNewswire)
21.07.22	[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022 (GlobeNewswire)
19.07.22	Roche's Elecsys Amyloid Plasma Panel granted FDA Breakthrough Device Designation to enable a timely diagnosis of Alzheimer’s disease (GlobeNewswire)
18.07.22	Roche launches innovative dual antigen and antibody diagnostic test supporting the fight to eliminate the hepatitis C virus (GlobeNewswire)
14.07.22	Eight-year data from APHINITY study show Roche’s Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer (GlobeNewswire)
14.07.22	New two-year data confirm Roche’s Vabysmo improves vision with fewer treatments for people with neovascular age-related macular degeneration (GlobeNewswire)
11.07.22	New data from phase III HAVEN 6 study reinforce favourable safety and efficacy profile of Roche’s Hemlibra in people with moderate or mild haemophilia A (GlobeNewswire)
06.07.22	FDA grants Priority Review to Roche’s Lunsumio for people with relapsed or refractory follicular lymphoma (GlobeNewswire)
29.06.22	Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care (GlobeNewswire)
28.06.22	Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics (GlobeNewswire)
16.06.22	Roche launches human papillomavirus (HPV) self-sampling solution, expanding cervical cancer screening options (GlobeNewswire)
16.06.22	Roche provides update on Alzheimer’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease (GlobeNewswire)
15.06.22	Roche receives FDA EUA for cobas SARS-CoV-2 Duo, the first PCR test to simultaneously detect COVID-19 and quantitatively measure viral load levels of COVID-19 (GlobeNewswire)
10.06.22	Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting (GlobeNewswire)
09.06.22	U.S. FDA approves Foundation Medicine’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib) (GlobeNewswire)
09.06.22	European Commission approves Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer (GlobeNewswire)
08.06.22	European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma (GlobeNewswire)
31.05.22	FDA approves Roche’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA) (GlobeNewswire)
27.05.22	New pivotal data demonstrate clinical benefit of Roche’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma (GlobeNewswire)
25.05.22	Roche’s Polivy combination approved by European Commission for people with previously untreated diffuse large B-cell lymphoma (GlobeNewswire)
25.05.22	Roche develops unique PCR tests to detect the monkeypox virus (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

mehr

23:29		Novartis-Aktie: Novartis muss sich erneut Schmiergeld-Vorwürfen stellen
21:39		Roche-CEO bescheinigt Pharmakonzern gesundes Geschäft
27.12.24		Anleger in New York halten sich zurück: Dow Jones beendet die Freitagssitzung im Minus
27.12.24		BioNTech und Pfizer zahlen Milliardenbetrag für Impfstoffvergleich in USA - BioNTech-Aktie fester
27.12.24		Dow Jones aktuell: Dow Jones verliert am Freitagnachmittag
27.12.24		Schwacher Wochentag in New York: Dow Jones verbucht am Freitagmittag Verluste
27.12.24		Freitagshandel in Frankfurt: LUS-DAX zeigt sich letztendlich fester
27.12.24		Optimismus in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen